Upgrade to SI Premium - Free Trial

Merck KGaA Reports FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

December 10, 2018 10:10 AM
Merck KGaA, Darmstadt, Germany, a leading science and technology company, which operates its healthcare business in the U.S. and Canada ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles